0001209191-21-057324.txt : 20210922 0001209191-21-057324.hdr.sgml : 20210922 20210922200233 ACCESSION NUMBER: 0001209191-21-057324 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210920 FILED AS OF DATE: 20210922 DATE AS OF CHANGE: 20210922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brumm Joshua T CENTRAL INDEX KEY: 0001528826 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 211270673 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-20 0 0001818794 Dyne Therapeutics, Inc. DYN 0001528826 Brumm Joshua T C/O DYNE THERAPEUTICS, INC. 830 WINTER STREET WALTHAM MA 02451 1 1 0 0 See Remarks Common Stock 2021-09-20 4 S 0 3425 15.61 D 103602 D Common Stock 2021-09-21 4 S 0 4584 16.11 D 99018 D Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.22 to $16.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in footnote (2) and (4) of this Form 4. Includes 80,270 unvested RSUs. The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 21, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.87 to $16.36, inclusive. Chief Executive Officer and President /s/ Richard Scalzo, Attorney-in-Fact 2021-09-22